Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720

Transplantation

Volumn 79, Issue 9, 2005, Pages 1051-1055

  Maki, Takashi ^a,b   Gottschalk, Rita ^a   Ogawa, Norihiko ^a   Monaco, Anthony P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Autoimmunity; Diabetes; Disease prevention; FTY720; Nonobese diabetic mice

Indexed keywords

FINGOLIMOD; GLUCOSE; INSULIN; ISOPHANE INSULIN; RAPAMYCIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED NOD; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 18644366150     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000161220.87548.EE     Document Type: Conference Paper

References (16)

1. Brinkmann V, Lynch KR. FTY720: Targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14: 569.
2. Nagahara Y, Ikekita M, Shinomiya T. T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br J Phamacol 2002; 137: 953.
3. Yanagawa Y, Hoshino Y, Kataoka H, et al. FY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts. Transplant Proc 1999; 31: 1227.
4. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 5761.
5. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: Efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2004; 77: 1926.
6. Maki T, Gottschalk R, Monaco AP. Prevention of autoimmune diabetes by FTY720 in NOD mice. Transplantation 2002; 74: 1684.
7. Pastorale C, Arata M, Caminos A, et al. Effect of modified diabetic splenocytes on mice injected with multiple low-dose streptozotocin. Exp Biol Med 2002; 227: 282.
8. Suzuki S, Li X-K, Enosawa S, et al. A new immunosuppressant, FTY720, induces bcl-2 associated apoptotic cell death in human lymphocytes. Immunology 1996; 89: 518.
9. Baeder WL, Sredy J, Sehgal SN, et al. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992; 89: 174.
10. Shapri AMJ, Suarez-Pinzon WL, Power R, et al. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia 2002; 45: 224.
11. Ogawa N, Minamimura K, Maki T. Administration of polyclonal anti-T cell antibody (ALS) after establishment of extensive insulitis prevents subsequent development of autoimmune diabetes in NOD mice, (submitted for publication)
12. Maki T, Ichikawa T, Blanco R, et al. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci USA 1992; 89: 3434.
13. Ogawa N, List J, Habener J, et al. Cure of overt type 1 diabetes in NOD mice by transient treatment with antilymphocyte serum and exendin-4. Diabetes 2004; 53: 1700.
14. Becker DJ, LaPorte RE, Libman I, et al. Prevention of type 1 diabetes: Is now the time? J Clin Endocrinol Metab 1999; 85: 498.
15. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221.
16. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692.